Vestcor Inc Purchases New Shares in TriSalus Life Sciences, Inc. (NASDAQ:TLSI)

Vestcor Inc acquired a new position in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 23,376 shares of the company’s stock, valued at approximately $108,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Walleye Capital LLC acquired a new position in shares of TriSalus Life Sciences in the third quarter valued at about $66,000. MSD Partners L.P. acquired a new position in shares of TriSalus Life Sciences during the 3rd quarter worth approximately $184,000. Wolverine Asset Management LLC acquired a new position in shares of TriSalus Life Sciences during the 2nd quarter worth approximately $240,000. Highbridge Capital Management LLC acquired a new stake in shares of TriSalus Life Sciences in the second quarter valued at approximately $1,184,000. Finally, Duquesne Family Office LLC boosted its stake in shares of TriSalus Life Sciences by 35.1% in the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after buying an additional 110,966 shares during the period. Institutional investors and hedge funds own 2.58% of the company’s stock.

Wall Street Analysts Forecast Growth

TLSI has been the topic of a number of recent research reports. Oppenheimer assumed coverage on TriSalus Life Sciences in a research note on Monday, September 16th. They set an “outperform” rating and a $10.00 price objective on the stock. Roth Mkm began coverage on TriSalus Life Sciences in a research report on Monday, November 11th. They issued a “buy” rating and a $11.00 price target on the stock. Northland Capmk raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Canaccord Genuity Group decreased their target price on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Finally, Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $12.08.

TriSalus Life Sciences Stock Down 1.5 %

NASDAQ:TLSI opened at $3.91 on Friday. TriSalus Life Sciences, Inc. has a twelve month low of $3.50 and a twelve month high of $10.42. The stock’s 50-day simple moving average is $4.19 and its 200 day simple moving average is $5.07. The firm has a market capitalization of $119.22 million, a PE ratio of -1.57 and a beta of 0.56.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.